Abstract
Immunosuppressant peptide immunocortin for the first time was described in 1993. It corresponds to residues 11–20 of human Ig heavy chain (conserved motif of VH domain). There are no data about production of immunocortin by proteolysis of Ig in vivo. Synthetic immunocortin in concentration ~ 10−9 M suppresses phagocytosis in peritoneal macrophages, ConA-dependent blast transformation of rat lymphocytes, exhibits ACTH-like neurotropic activity and was suggested as a potential drug for treatment of a multiple sclerosis (MS). Here, we report a sequence and method of synthesis of Abu-TGIRIS-Abu-NH2 (Abu, alpha-aminobutyric acid), an artificial analogue of immunocortin. Biological trials of peritoneally injected Abu-TGIRIS-Abu-NH2 gave an evidence of its better efficacy versus immunocortin in a test for suppression of the experimental autoimmune encephalomyelitis (EAE) in Dark Agouti (DA) rats.
Highlights
Multiple sclerosis (MS) is a severe neurological condition of autoimmune origin with a worldwide distribution
Myelin is composed with myelin basic protein (MBP), proteolipid protein (PLP), myelin-associated glycoprotein (MAG), and
On the basis of clinical manifestation, MS is divided into four categories: relapsing-remitting MS (RRMS)—85% from registered MS cases; primary progressing MS (PPMS)—10% cases; SPMS—secondary progressing MS; and progressing-remitting MS (PRMS)—5% cases [4]
Summary
Multiple sclerosis (MS) is a severe neurological condition of autoimmune origin with a worldwide distribution. The 2012 MS prevalence in the USA was 149.2 per 100,000 individuals (95% confidence interval 147.6–150.9). On the basis of clinical manifestation, MS is divided into four categories: relapsing-remitting MS (RRMS)—85% from registered MS cases; primary progressing MS (PPMS)—10% cases; SPMS—secondary progressing MS (develops in patients with RRMS); and progressing-remitting MS (PRMS)—5% cases [4]. Both T- and B-lymphocytes are involved to MS initiation and progression. B-lymphocytes infiltrated to cerebrospinal liquid through hematoencephalic barrier are responsible for oligoclonal antibodies some of which exhibit low affinity to myelin [5]. These B-lymphocytes are prone to an enhanced synthesis of a lymphoproliferative cytokine GM-CSF [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
